Abstract
Myeloid-mediated immunosuppression is a potential mechanism of resistance to PD-1 immune checkpoint inhibitors (ICI) in metastatic (m)NSCLC. Our group has previously demonstrated that expansion of myeloid derived suppressor cells (MDSC), of which the neutrophil-to-lymphocyte ratio (NLR) acts as a surrogate, is associated with poor survival to ICI treatment. We hypothesized that patients with high NLR may preferentially benefit from combination ICI with chemotherapy as a myeloid debulking therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
